EA200000274A2 - Способы получения и промежуточные соединения для получения противораковых соединений - Google Patents

Способы получения и промежуточные соединения для получения противораковых соединений

Info

Publication number
EA200000274A2
EA200000274A2 EA200000274A EA200000274A EA200000274A2 EA 200000274 A2 EA200000274 A2 EA 200000274A2 EA 200000274 A EA200000274 A EA 200000274A EA 200000274 A EA200000274 A EA 200000274A EA 200000274 A2 EA200000274 A2 EA 200000274A2
Authority
EA
Eurasian Patent Office
Prior art keywords
obtaining
compounds
methods
tray
intermediate connections
Prior art date
Application number
EA200000274A
Other languages
English (en)
Other versions
EA200000274A3 (ru
EA004654B1 (ru
Inventor
Ричард Шелтон Лехнер
Тимоти Норрис
Динос Пол Сантафьянос
Original Assignee
Пфайзер Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк.
Publication of EA200000274A2 publication Critical patent/EA200000274A2/ru
Publication of EA200000274A3 publication Critical patent/EA200000274A3/ru
Publication of EA004654B1 publication Critical patent/EA004654B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0002—Preliminary treatment
    • C22B15/0004—Preliminary treatment without modification of the copper constituent
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0063—Hydrometallurgy
    • C22B15/0065—Leaching or slurrying
    • C22B15/0067—Leaching or slurrying with acids or salts thereof
    • C22B15/0071—Leaching or slurrying with acids or salts thereof containing sulfur
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P10/00—Technologies related to metal processing
    • Y02P10/20—Recycling

Abstract

Данное изобретение относится к способам получения и промежуточным соединениям для получения соединений формулы 1и их фармацевтически приемлемых солей и сольватов, а также родственным по структуре соединениям, где R, Rи Rопределены как указано в описании. Вышеназванные соединения применимы при лечении заболеваний с гиперпролиферацией, таких как разновидности рака у млекопитающих.
EA200000274A 1999-03-31 2000-03-30 Способы получения и промежуточные соединения для получения противораковых соединений EA004654B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12707299P 1999-03-31 1999-03-31

Publications (3)

Publication Number Publication Date
EA200000274A2 true EA200000274A2 (ru) 2000-10-30
EA200000274A3 EA200000274A3 (ru) 2003-02-27
EA004654B1 EA004654B1 (ru) 2004-06-24

Family

ID=22428179

Family Applications (3)

Application Number Title Priority Date Filing Date
EA200201244A EA005561B1 (ru) 1999-03-31 2000-03-30 Способ получения промежуточных соединений, применимых для получения противораковых соединений
EA200000274A EA004654B1 (ru) 1999-03-31 2000-03-30 Способы получения и промежуточные соединения для получения противораковых соединений
EA200201245A EA005892B1 (ru) 1999-03-31 2000-03-30 Способ получения противораковых соединений

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200201244A EA005561B1 (ru) 1999-03-31 2000-03-30 Способ получения промежуточных соединений, применимых для получения противораковых соединений

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200201245A EA005892B1 (ru) 1999-03-31 2000-03-30 Способ получения противораковых соединений

Country Status (50)

Country Link
US (1) US6476040B1 (ru)
EP (1) EP1044969B1 (ru)
JP (2) JP3420549B2 (ru)
KR (2) KR100430210B1 (ru)
CN (2) CN1215061C (ru)
AP (2) AP1265A (ru)
AR (1) AR018705A1 (ru)
AT (1) ATE348098T1 (ru)
AU (2) AU781402B2 (ru)
BG (1) BG65194B1 (ru)
BR (1) BRPI0001486B8 (ru)
CA (2) CA2427221C (ru)
CO (1) CO5160273A1 (ru)
CR (1) CR6165A (ru)
CZ (1) CZ299426B6 (ru)
DE (1) DE60032275T2 (ru)
DK (1) DK1044969T3 (ru)
DZ (1) DZ3030A1 (ru)
EA (3) EA005561B1 (ru)
EE (1) EE04589B1 (ru)
EG (1) EG22506A (ru)
ES (1) ES2278578T3 (ru)
GE (1) GEP20022653B (ru)
GT (1) GT200000037A (ru)
HK (1) HK1029790A1 (ru)
HR (1) HRP20000182B1 (ru)
HU (1) HU227698B1 (ru)
ID (1) ID25427A (ru)
IL (2) IL135245A0 (ru)
IS (1) IS2468B (ru)
MA (1) MA25087A1 (ru)
MY (1) MY136270A (ru)
NO (2) NO321952B1 (ru)
NZ (2) NZ503683A (ru)
OA (1) OA11335A (ru)
PA (1) PA8491901A1 (ru)
PE (1) PE20001599A1 (ru)
PL (1) PL339330A1 (ru)
PT (1) PT1044969E (ru)
RS (1) RS49836B (ru)
SG (2) SG121687A1 (ru)
SK (1) SK287339B6 (ru)
SV (1) SV2002000047A (ru)
TN (1) TNSN00064A1 (ru)
TR (1) TR200000837A2 (ru)
TW (1) TW553939B (ru)
UA (2) UA70928C2 (ru)
UY (1) UY26086A1 (ru)
YU (1) YU13200A (ru)
ZA (1) ZA200001586B (ru)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
UA74803C2 (ru) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стойкий полиморф гидрохлорида n-(3-этинилфенил)-6,7-бис(2-метоксиэтокси)-4-хиназолинамина, способ его получения (варианты) и фармацевтическое применение
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
KR100589032B1 (ko) 2000-10-20 2006-06-14 에자이 가부시키가이샤 질소 함유 방향환 유도체
AU2002350105A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
EP1521747B1 (en) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
US7148231B2 (en) * 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
JPWO2004080462A1 (ja) 2003-03-10 2006-06-08 エーザイ株式会社 ｃ−Ｋｉｔキナーゼ阻害剤
AU2004253967B2 (en) 2003-07-03 2010-02-18 Cytovia, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
US8309562B2 (en) * 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
MXPA06002964A (es) 2003-09-16 2006-06-14 Astrazeneca Ab Derivados de quinazolina como inhibidores de cinasa de tirosina.
EP1673085B1 (en) 2003-09-26 2011-11-09 Exelixis, Inc. C-met modulators and methods of use
WO2005044788A1 (ja) 2003-11-11 2005-05-19 Eisai Co., Ltd. ウレア誘導体およびその製造方法
DK1746999T3 (da) * 2004-05-06 2012-01-23 Warner Lambert Co 4-phenylamino-quinazolin-6-yl-amider
ES2322175T3 (es) 2004-09-17 2009-06-17 EISAI R&D MANAGEMENT CO., LTD. Composicion medicinal con estabilidad mejorada y gelificacion reducida.
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US7625911B2 (en) * 2005-01-12 2009-12-01 Mai De Ltd. Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
WO2006090930A1 (ja) 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. スルホンアミド化合物の新規併用
EP1925941B1 (en) * 2005-08-01 2012-11-28 Eisai R&D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
WO2007052850A1 (ja) 2005-11-07 2007-05-10 Eisai R & D Management Co., Ltd. 血管新生阻害物質とc-kitキナーゼ阻害物質との併用
WO2007061127A1 (ja) * 2005-11-22 2007-05-31 Eisai R & D Management Co., Ltd. 多発性骨髄腫に対する抗腫瘍剤
CN104706637A (zh) 2006-05-18 2015-06-17 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
JPWO2008001956A1 (ja) * 2006-06-29 2009-12-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝線維症治療剤
CA2659307A1 (en) 2006-07-28 2008-01-31 Synthon B.V. Crystalline erlotinib
CN101511793B (zh) 2006-08-28 2011-08-03 卫材R&D管理有限公司 针对未分化型胃癌的抗肿瘤剂
US8372856B2 (en) 2006-10-27 2013-02-12 Synthon Bv Hydrates of erlotinib hydrochloride
CN101616671A (zh) 2007-01-19 2009-12-30 卫材R&D管理有限公司 胰腺癌治疗用组合物
US8962655B2 (en) 2007-01-29 2015-02-24 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
EP2170844B1 (en) 2007-02-21 2016-05-04 Natco Pharma Limited Novel polymorphs of erlotinib hydrochloride and method of preparation
AU2008235274B2 (en) 2007-04-04 2013-04-18 Cipla Limited Process for preparation of erlotinib and its pharmaceutically acceptable salts
US20090012295A1 (en) * 2007-06-25 2009-01-08 Ales Gavenda Amorphous Erlotinib, processes for the preparation thereof, and processes to prepare additional forms of Erlotinib
ES2492645T3 (es) 2007-07-11 2014-09-10 Hetero Drugs Limited Un procedimiento mejorado para la preparación de hidrocloruro de erlotinib
US20090124642A1 (en) * 2007-08-23 2009-05-14 Augusto Canavesi Crystalline forms of Erlotinib HCI and formulations thereof
TW200925152A (en) * 2007-08-23 2009-06-16 Plus Chemicals S A Processes for the preparation of crystalline forms A, B and pure crystalline form a of erlotinib HCL
US20090076042A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched erlotinib
AU2008325608B2 (en) 2007-11-09 2013-03-14 Eisai R & D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
KR101506062B1 (ko) * 2008-01-29 2015-03-25 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 저해 물질과 탁산의 병용
US20090269354A1 (en) * 2008-03-28 2009-10-29 Concert Pharmaceuticals, Inc. Quinazoline derivatives and methods of treatment
KR20110017907A (ko) * 2008-07-07 2011-02-22 플러스 케미칼스, 에스.에이. 엘로티닙 염기 및 엘로티닙 ｈｃｌ의 결정형
KR101132937B1 (ko) 2008-10-01 2012-04-06 주식회사종근당 Ｎ-(3-에티닐페닐)-6,7-비스(2-메톡시에톡시)-4-퀴나졸린아민 납실레이트 염
WO2010040212A1 (en) * 2008-10-08 2010-04-15 Apotex Pharmachem Inc. Processes for the preparation of erlotinib hydrochloride
KR101733773B1 (ko) 2009-01-16 2017-05-10 엑셀리시스, 인코포레이티드 Ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
US8440823B2 (en) 2009-03-26 2013-05-14 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
WO2011058525A2 (en) 2009-11-12 2011-05-19 Ranbaxy Laboratories Limited Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
WO2011068404A2 (en) 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Administration of n-(3-ethynylphenylamino)-6,7-bis(2- methoxyethoxy)-4-quinazolinamine mesylate salt by inhalation
ES2573515T3 (es) 2010-06-25 2016-06-08 Eisai R&D Management Co., Ltd. Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados
JP5948597B2 (ja) 2010-07-23 2016-07-06 ジェネリクス・［ユーケー］・リミテッド 純粋なエルロチニブ
IT1402029B1 (it) 2010-10-14 2013-08-28 Italiana Sint Spa Procedimento per la preparazione di erlotinib
US8962650B2 (en) 2011-04-18 2015-02-24 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN102267952B (zh) * 2011-06-21 2013-12-11 天津市汉康医药生物技术有限公司 喹唑啉类化合物、其制备方法和用途
CN103420924B (zh) * 2012-05-25 2016-08-31 浙江九洲药业股份有限公司 一种盐酸埃罗替尼晶型a的制备方法
WO2014037961A1 (en) 2012-09-04 2014-03-13 Shilpa Medicare Limited Crystalline erlotinib hydrochloride process
JPWO2014098176A1 (ja) 2012-12-21 2017-01-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体のアモルファス及びその製造方法
WO2014118737A1 (en) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Erlotinib salts
EP2997377B1 (en) 2013-05-14 2018-07-18 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN103333124B (zh) * 2013-05-28 2015-03-25 埃斯特维华义制药有限公司 一种制备盐酸厄洛替尼晶型f的方法
MX2017001980A (es) 2014-08-28 2017-05-04 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y metodo para su produccion.
CA2908441A1 (en) 2014-10-28 2016-04-28 Cerbios-Pharma Sa Process for the preparation of erlotinib
SG11201706630UA (en) 2015-02-25 2017-09-28 Eisai R&D Man Co Ltd Method for suppressing bitterness of quinoline derivative
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
MX2017015896A (es) 2015-06-16 2018-08-09 Eisai R&D Man Co Ltd Agente anticancerigeno.
CN105884653A (zh) * 2016-06-08 2016-08-24 浙江汇能生物股份有限公司 一种埃罗替尼衍生物及其制备方法
CN106279585A (zh) * 2016-08-26 2017-01-04 宁波圣达精工智能科技有限公司 一种阻燃智能密集书架的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4747498A (en) * 1986-06-27 1988-05-31 Sunbeam Plastics Corporation Safety dispensing closure-container package
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
ES2332984T3 (es) * 1995-03-30 2010-02-16 Pfizer Products Inc. Derivados de quinazolinas.
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
WO1997032856A1 (en) 1996-03-05 1997-09-12 Zeneca Limited 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6225499B1 (en) 1997-07-14 2001-05-01 Catalytica Pharmaceuticals, Inc. Process for preparing aminoarylacetylenes
JP4652569B2 (ja) 1998-04-29 2011-03-16 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド Ｎ−（３−エチニルフェニルアミノ）−６，７−ビス（２−メトキシエトキシ）−４−キナゾリンアミンメシレートの無水物及び一水和物

Also Published As

Publication number Publication date
HU227698B1 (en) 2011-12-28
OA11335A (en) 2003-12-10
PT1044969E (pt) 2007-05-31
KR100430210B1 (ko) 2004-05-03
EA200201245A1 (ru) 2003-04-24
BG104278A (en) 2001-08-31
CN1215061C (zh) 2005-08-17
CR6165A (es) 2008-10-10
NO321952B1 (no) 2006-07-24
AP1265A (en) 2004-03-26
SK4442000A3 (en) 2000-10-09
EG22506A (en) 2003-03-31
EP1044969A2 (en) 2000-10-18
KR100430209B1 (ko) 2004-05-03
ZA200001586B (en) 2001-10-01
EA200201244A1 (ru) 2003-04-24
KR20010014658A (ko) 2001-02-26
MA25087A1 (fr) 2000-10-01
HRP20000182B1 (en) 2007-10-31
IL168036A (en) 2006-12-10
NO324745B1 (no) 2007-12-03
TNSN00064A1 (fr) 2005-11-10
NZ503683A (en) 2001-09-28
UA80955C2 (en) 2007-11-26
GT200000037A (es) 2001-09-21
SG121687A1 (en) 2006-05-26
GEP20022653B (en) 2002-03-25
EA005892B1 (ru) 2005-06-30
TR200000837A2 (tr) 2000-11-21
SG115536A1 (en) 2005-10-28
EP1044969A3 (en) 2000-11-29
NO20001648L (no) 2000-10-02
DE60032275T2 (de) 2007-07-12
EA200000274A3 (ru) 2003-02-27
EE200000255A (et) 2000-12-15
ES2278578T3 (es) 2007-08-16
ATE348098T1 (de) 2007-01-15
AU2005201494B2 (en) 2008-02-07
CN1276370A (zh) 2000-12-13
TW553939B (en) 2003-09-21
JP2003176274A (ja) 2003-06-24
DE60032275D1 (de) 2007-01-25
NZ512818A (en) 2003-01-31
PL339330A1 (en) 2000-10-09
HRP20000182A2 (en) 2001-04-30
BRPI0001486B1 (pt) 2019-01-29
IL135245A0 (en) 2001-05-20
EP1044969B1 (en) 2006-12-13
CN100351242C (zh) 2007-11-28
US6476040B1 (en) 2002-11-05
DZ3030A1 (fr) 2004-03-27
DK1044969T3 (da) 2007-04-23
BG65194B1 (bg) 2007-06-29
CA2427221A1 (en) 2000-09-30
CA2427221C (en) 2008-09-16
IS2468B (is) 2008-12-15
AU781402B2 (en) 2005-05-19
NO20001648D0 (no) 2000-03-30
CZ299426B6 (cs) 2008-07-23
IS5411A (is) 2000-10-02
JP4074509B2 (ja) 2008-04-09
PE20001599A1 (es) 2001-01-18
SV2002000047A (es) 2002-01-23
YU13200A (sh) 2002-10-18
HU0001353D0 (en) 2000-06-28
ID25427A (id) 2000-10-05
EA005561B1 (ru) 2005-04-28
AU2005201494A1 (en) 2005-05-05
AP2000001778A0 (en) 2000-03-31
AU2262000A (en) 2000-10-05
UY26086A1 (es) 2000-10-31
EA004654B1 (ru) 2004-06-24
RS49836B (sr) 2008-08-07
AP1655A (en) 2006-09-01
JP2000290262A (ja) 2000-10-17
CN1699350A (zh) 2005-11-23
AR018705A1 (es) 2001-11-28
NO20054715L (no) 2000-10-02
MY136270A (en) 2008-09-30
SK287339B6 (sk) 2010-07-07
HUP0001353A2 (hu) 2001-05-28
CO5160273A1 (es) 2002-05-30
CZ20001155A3 (cs) 2001-03-14
PA8491901A1 (es) 2001-12-14
JP3420549B2 (ja) 2003-06-23
UA70928C2 (ru) 2004-11-15
BRPI0001486B8 (pt) 2021-05-25
HUP0001353A3 (en) 2002-01-28
KR20020084903A (ko) 2002-11-13
HK1029790A1 (en) 2001-04-12
EE04589B1 (et) 2006-02-15
CA2302965A1 (en) 2000-09-30
BR0001486A (pt) 2001-05-02
CA2302965C (en) 2004-02-17

Similar Documents

Publication Publication Date Title
EA200000274A2 (ru) Способы получения и промежуточные соединения для получения противораковых соединений
EA200200716A1 (ru) Арилконденсированные азаполициклические соединения
EA200000592A1 (ru) Азаполициклические соединения, конденсированные с арилом
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
GT199900019A (es) Formulas farmaceuticamente estables de solucion de oxaliplatino.
EA200200509A1 (ru) Новые производные бензоимидазола, используемые в качестве антипролиферативного средства
EA200100412A1 (ru) Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ
EA200201277A1 (ru) Замещенные бициклические производные для лечения аномального роста клеток
EA200001224A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200100135A1 (ru) Алкинилзамещенные производные хинолин-2-она, полезные в качестве противораковых агентов
EA200300248A1 (ru) Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
MA27769A1 (fr) Dérivées de 2-acylamino-4-phenylthiazole, leur préparation et leur application en thérapeutique
EA200001223A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200500174A1 (ru) Новые производные бензимидазола, полезные в качестве антипролиферативных агентов
EA200100766A1 (ru) Хинолин-2-он замещенные гетероарильные производные, используемые в качестве противоопухолевых агентов
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
EA200100983A1 (ru) Производные 13-метилэритромицина
EA200100971A1 (ru) Новые соединения и композиции в качестве ингибиторов протеазы
EA199901014A1 (ru) C-4"-замещенные макролидные производные
CA2359772A1 (en) Cyclic substituted fused pyrrolocarbazoles and isoindolones
EA200401528A1 (ru) Производные диарилсульфидов, способ их получения и промежуточные соединения
EA200401114A3 (ru) Замещённые гидроксиэтиламины
IL153680A0 (en) Aplidine derivatives and methods for the preparation thereof
EA200000996A1 (ru) Конденсированные с арилом азаполициклические соединения
ATE386742T1 (de) Imidazonaphthyridine

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MK4A Patent expired

Designated state(s): RU